Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Annabel Meireson

Awards & Distinctions

14 Results

2022

Biomarkers in immuno-oncology : from melanoma to other cancer types, from tissue to liquid biopsy, from late stage to early stage disease

Annabel MeiresonLieve BrochezLiesbeth FerdinandeVibeke Kruse

2021

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Mathieu SpaasNora SundahlEva HulstaertVibeke KruseSylvie RotteyDaan De MaeseneerVeerle SurmontAnnabel MeiresonLieve BrochezDries Reynders et al.

A1 Journal Article in BMC CANCER

Clinical relevance of serum Kyn/Trp ratio and basal and IFN gamma-upregulated IDO1 expression in peripheral monocytes in early stage melanoma

Annabel MeiresonLiesbeth FerdinandeMarc HaspeslaghBenjamin HennartDelphine AllorgePiet OstNora SundahlMathieu SpaasAnnelies DemeyerLieve Brochez

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Annabel MeiresonSimon TavernierSofie Van GassenNora SundahlAnnelies DemeyerMathieu SpaasVibeke KruseLiesbeth FerdinandeJo Van DorpeBenjamin Hennart et al.

A1 Journal Article in CANCERS

2020

IDO expression in cancer : different compartment, different functionality?

Annabel MeiresonMichael DevosLieve Brochez

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

2019

Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Nora SundahlTeofila SeremetJo Van DorpeBart NeynsLiesbeth FerdinandeAnnabel MeiresonLieve BrochezVibeke KrusePiet Ost

A1 Journal Article in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

Piet OstNora SundahlG VandekerkhoveKarel DecaesteckerAnnabel MeiresonPieter De VisschereValerie FonteyneDaan De MaeseneerDries ReyndersEls Goetghebeur et al.

Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Nora SundahlGillian VandekerkhoveKarel DecaesteckerAnnabel MeiresonPieter De VisschereValerie FonteyneDaan De MaeseneerDries ReyndersEls GoetghebeurJo Van Dorpe et al.

A1 Journal Article in EUROPEAN UROLOGY

Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results

Gillian VandekerkhoveNora SundahlKarel DecaesteckerAnnabel MeiresonPieter De VisschereValerie FonteyneDaan De MaeseneerDries ReyndersEls GoetghebeurJo Van Dorpe et al.

2018

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Lieve BrochezAnnabel MeiresonINES CHEVOLETNora SundahlPiet OstVibeke Kruse

A1 Journal Article in NATURE COMMUNICATIONS

Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis

Annabel MeiresonINES CHEVOLETEva HulstaertLiesbeth FerdinandePiet OstKaren GeboesMarc De ManDirk Van de PutteLaurine VersetVibeke Kruse et al.

Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile

Annabel MeiresonINES CHEVOLETEva HulstaertLiesbeth FerdinandePiet OstKaren GeboesMarc De ManDirk Van de PutteLaurine VersetVibeke Kruse et al.

A2 Journal Article in ONCOTARGET

Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma

Nora SundahlKatrien De WolfVibeke KruseAnnabel MeiresonDries ReyndersEls GoetghebeurMireille Van GeleReinhart SpeeckaertBenjamin HennartLieve Brochez et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

2017

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma : evaluation of safety and clinical and immunologic response

Nora SundahlKatrien De WolfSylvie RotteyKarel DecaesteckerDaan De MaeseneerAnnabel MeiresonEls GoetghebeurValerie FonteyneSofie VerbekePieter De Visschere et al.

A1 Journal Article in JOURNAL OF TRANSLATIONAL MEDICINE